Ionis Pharmaceuticals, Inc. Common Stock

IONSNASDAQ • USD
ThemeGenomics & Precision Med.›RNA Therapeutics
54.82 USD
↗ 0.09 (0.16%)🟢LIVE (AS OF 02:14 PM EDT)
🟢Market: OPEN

IONS is currently priced at $54.82. The stock presents a bearish profile across the board: technical indicators signal "Strong Sell" and our fundamental models agree with a "Sell" rating. This is driven by a concerning Altman Z-Score in the distress zone, negative Return on Equity, a bearish Death Cross on the long-term moving averages and bearish long-term moving average alignment. On the valuation front, IONS trades at elevated multiples relative to its peers, earning a "Richly Valued" assessment.

Technical & fundamental data as of Jul 15, 2026.

Open?$53.95
High?$55.92
Low?$53.49
Prev. Close?$54.73
Volume?2.4M
Avg. Volume?3.2M
VWAP?$54.84
Rel. Volume?0.74x
Bid / Ask
Bid?$51.94 × 100
Ask?$54.66 × 100
Spread?$2.72
Midpoint?$53.30
Valuation & Ratios
Market Cap?9.0B
Shares Out?165.3M
Float?162.8M
Float %?98.5%
P/E Ratio?N/A
P/B Ratio?18.41
EPS?-$1.98
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis marked its first two independent launches in 2025 for Tryngolza (for FCS) and Dawnzera (for HAE).
Themes
Healthcare - Genomics & Precision Medicine›RNA TherapeuticsBiotech - Drug Development›Rare Disease Therapeutics
Employees
1.4K
Market Cap
9.0B
Industry
PHARMACEUTICAL PREPARATIONS
Website
www.ionis.com
Listed
1991-05-17
Address
2855 GAZELLE COURT
CARLSBAD, CA 92010
Phone: (760) 931-9200
Technical OutlookStrong Sell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-3/3)
Medium-Term (Wave)?▼ Bearish(-2/3)
Short-Term (Ripple)?▼ Bearish(-3/3)
MA Alignment?Bearish Alignment
Full Technical Analysis →
Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?
23
Z-Score?
15
Momentum?
62
Short Sent.?
34
Piotroski F-Score?3/9Weak
Altman Z-Score?1.25Distress
Confidence?68%Moderate
Full Fundamental Analysis →
Short InterestHigh
Short % of Float?10.70%High
Short Interest?17.4M
Days to Cover?7.3
Free Float162.8M
Avg Daily Volume2.4M
Settlement Date2026-06-30
Financial Health
Current Ratio?3.22Strong
Quick Ratio?3.21Strong
Cash Ratio?0.24Low
Debt/Equity?3.57High
ValuationRICHLY VALUEDvs 1 peers + S&P 500
Score
50/100
P/E?
N/A▾
P/B?
Peers
100
S&P
8
18.41HIGH▾
P/S?
Peers
100
S&P
11
8.55HIGH▾
P/FCF?
N/A▾
EV/EBITDA?
S&P
97
-31.2CHEAP▾
EV/Sales?
Peers
100
S&P
11
10.04HIGH▾
Returns & Efficiency
ROE?
S&P
3
-66.5%WEAK▾
ROA?
S&P
3
-9.5%WEAK▾
Cash Flow & Enterprise
FCF?$-971257000
Enterprise Value?$10.6B
Fundamentals ratios updated end of day
MarketsMoversWatchlist